Valuation: Photocure ASA

Market Cap 1.32B 139M 122M 115M 105M 196M 13.3B 197M 1.38B 533M 6.79B 520M 509M 21.81B P/E 2026 *
17.6x
P/E 2027 * 63.8x
Enterprise Value 1.15B 121M 106M 100M 91.11M 171M 11.59B 172M 1.2B 465M 5.92B 453M 444M 19.01B EV / Sales 2026 *
1.75x
EV / Sales 2027 * 1.74x
Free-Float
94.52%
Yield 2026 *
-
Yield 2027 * -
1 day-5.99%
Current month-5.99%
1 month-5.99%
3 months-8.58%
6 months-20.08%
Current year-19.29%
1 month 5.65
Extreme 5.65
5.65
Current year 5.65
Extreme 5.65
7.39
1 year 5.58
Extreme 5.58
7.39
3 years 4.32
Extreme 4.32
7.39
5 years 4.21
Extreme 4.21
12.61
10 years 3
Extreme 3
17.57
Manager TitleAgeSince
Chief Executive Officer - 2018-10-31
Chief Tech/Sci/R&D Officer - 2021-07-31
Human Resources Officer - 2021-01-31
Director TitleAgeSince
Director/Board Member - 2021-12-31
Chairman - 2023-09-26
Director/Board Member - 2024-05-22
Change 5-day change 1-year change 3-year change Capi.($)
-5.99%0.00% - - 141M
+0.41%+1.99%+63.53%+118.21% 1,055B
+0.38%+0.85%+49.63%+73.22% 654B
+1.08%+0.92%+19.60%+75.30% 467B
-1.36%-2.58%+38.77%+42.33% 348B
+1.34%+4.53%+22.56%+29.55% 275B
-0.48%-0.54%+12.66%+13.50% 258B
+0.93%+6.45%+52.76%+54.53% 224B
+0.99%+1.30%+35.42%+102.22% 187B
-0.30%-2.98%-28.24%-61.28% 171B
Average -0.28%+0.74%+29.63%+49.73% 404.26B
Weighted average by Cap. +0.36%+1.32%+39.91%+70.08%

Financials

2026 *2027 *
Net sales 658M 69.15M 60.82M 57.51M 52.16M 97.96M 6.64B 98.53M 689M 266M 3.39B 260M 254M 10.88B 666M 69.99M 61.56M 58.21M 52.8M 99.15M 6.72B 99.73M 697M 269M 3.43B 263M 257M 11.02B
Net income 76.33M 8.02M 7.05M 6.67M 6.05M 11.36M 770M 11.42M 79.84M 30.84M 393M 30.1M 29.45M 1.26B 21M 2.21M 1.94M 1.83M 1.66M 3.12M 212M 3.14M 21.96M 8.48M 108M 8.28M 8.1M 347M
Net Debt -169M -17.75M -15.61M -14.76M -13.39M -25.15M -1.7B -25.29M -177M -68.27M -870M -66.65M -65.2M -2.79B -157M -16.49M -14.5M -13.71M -12.44M -23.36M -1.58B -23.5M -164M -63.42M -808M -61.91M -60.57M -2.6B
Logo Photocure ASA
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Employees
100
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
49.80NOK
Average target price
79.67NOK
Spread / Average Target
+59.97%

Quarterly revenue - Rate of surprise